期刊文献+

HIV-1膜蛋白gp140三聚体疫苗的构建和免疫原性研究

Construction and immunization of HIV-1 envelope glycoprotein trimer gp140 vaccine
原文传递
导出
摘要 目的构建表达中国流行株HIV-1CRF_07B/C亚型(HIV-1CN54)膜蛋白gp140和gp140FdFc三聚体疫苗,比较其免疫原性。方法构建gp140和gp140FdFc重组质粒,将质粒分别瞬时转染293F细胞,120小时后收获上清液,经纯化、浓缩、PBS置换、BCA试剂盒检测蛋白质浓度后,利用SDS-PAGE电泳检测蛋白分子量大小及纯度,酶联免疫吸附试验(ELISA)检测其与阳性病人血清的反应性。通过肌肉注射的方式分别免疫兔子,取兔子血清,ELISA检测血清抗体,并通过假病毒系统检测血清中和抗体滴度,比较gp140和gp140FdFc的免疫原性。结果成功获得基因重组gp140和gp140FdFc蛋白。免疫兔子后,gp140和gp140FdFc蛋白质均有很强的体液免疫应答,抗gp160抗体滴度分别为2.24×105和4.48×105,但gp140组未诱导出中和抗体,gp140FdFc组对4种假病毒具有一定的中和活性。结论 Gp140FdFc三聚体能诱导兔子产生较强的结合抗体和一定的中和抗体反应,可作为潜在的HIV-1免疫原进行疫苗研究。 Objective To construct and express the recombinant envelope glycoproteins gp140 and gp140FdFc of China HIV-1 subtypes B/C (CN54) with stable trimer conformation and compare their immunogenicity. MethodsAfter constructing gp140 and gp140FdFc plasmids, the recombinant plasmids were transfected into 293F cells andthe supernatants were collected 120 hours after transfection. After purification and concentration, the proteins ofgp140FdFc and gp140 were identified by SDS-PAGE and ELISA, accurately determined by BCA Protein Assay Kit.The proteins were used to immunize rabbits intramuscularly and blood samples were collected. Then, serum anti-bodies were detected by ELISA and neutralizing antibodies were detected by pseudovirus system to compare the im-munogenicity of gp140 and gp140FdFc. Results SDS-PAGE and Western-blot indicated that the proteins ofgp140FdFc and gp140 were successfully expressed in 293F cells. The proteins of gp140 and gp140FdFc producedstrong humoral immune responses after immunizing rabbits and the titers of gp 160 were 2.24 X l0^5 and 4. 48 x10^5 ,respectively. However, there was no neutralizing antibody in gp140 groups. Neutralizing antibody in gp140FdFcgroup can neutralize 4 pseudoviruses to some degree. Conclusions Gp140FdFc trimer could stimulate strong im-mune response and induce the neutralizing antibody and might be a potential immunogen in research of HIV in vac-cine.
出处 《中国艾滋病性病》 CAS 2014年第3期149-153,共5页 Chinese Journal of Aids & STD
基金 国家科技重大专项(2012ZX10001008-012) 传染病预防控制国家重点实验室(2012SKLID402)~~
关键词 Ⅰ型艾滋病病毒CN54株 疫苗 gp140三聚体 中和抗体 HIV-1CN54 Vaccine gp140 trimer Neutralizing antibody
  • 相关文献

参考文献15

  • 1Wu XL, Yang ZY, Li YX. Rational Design of Envelope IdentifiesBroadly Neutralizing Human Monoclonal Antibodies to HIV-1 [J]. Science, 2010, 329(5993): 856-861. 被引量:1
  • 2McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization[J]. J Exp Med, 2013, 210(2): 209--223. 被引量:1
  • 3Leaman DP, Zwiek MB. Increased functional stability and homo- geneity of viral envelope spikes through directed evolution[J]. PLoS Pathog, 2013, 9(2) e1003184. 被引量:1
  • 4Burton DR, Desrosiers RC, Doms RW, et al. Method of inducing neutralizing antibodies to human immunodeficiency virus[J]. Nat Immunol, 2004, 5(3): 233--236. 被引量:1
  • 5张聪优,万延民,许雪梅,徐建青.HIV-1包膜蛋白疫苗免疫原选择及改造策略研究进展[J].中华微生物学和免疫学杂志,2010,30(9):875-880. 被引量:5
  • 6Hutniek NA, Myles DJ,Bian CB, et al. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo[J]. Curr Opin Virol, 2011, 1(4): 233-240. 被引量:1
  • 7Qi Z, Pan CG, Lu H, etal. A recombinant mimetics of the HIV- 1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice[J]. BBRC, 2010, 398(3) : 506--512. 被引量:1
  • 8胡新韬,洪坤学,赵春红,郝晓培,郑扬,任莉,阮玉华,邵一鸣.HIV-1B’亚型及CRF07_BC重组毒株感染者中和反应特征分析[J].中国热带医学,2011,11(4):391-394. 被引量:8
  • 9Letvin N, Huang Y, Chakrabarti BK, et al. Heterologous enve-lope immunogens contribute to AIDS vaccine protection in Rhesus monkeys[J]. J Virol, 2004, 78(14) : 7490--7497. 被引量:1
  • 10Amara RR, Smith JM, Staprans SI, et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodefieien- ey virus 89.6P challenge by a DNA prime/recombinant modified vaecinia virus Ankara vaceine[J]. J Virol, 2002, 76(12): 6138 -6146. 被引量:1

二级参考文献75

  • 1王淑华,邢辉,王建军,苏斌,陈曦,全宇,赵全璧,阮玉华,徐建青,宋艳辉,邵一鸣.安徽阜阳既往献血人群HIV-1感染者基因变异特征的研究[J].中华医学杂志,2007,87(22):1535-1539. 被引量:8
  • 2Flynn NM,Forthal DN,Harro CD,et al.Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.J Infect Dis,2005,191(5):654-665. 被引量:1
  • 3Pitisuttithum P,Gilbert P,Gurwith M,et al.Randomized,double-blind,placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok,Thailand.J Infect Dis,2006,194(12):1661-1671. 被引量:1
  • 4Russell ND,Graham BS,Keefer MC,et al.Phase 2 study of an HIV-1 canarypox vaccine(vCP1452)alone and in combination with rgpl20:negative results fail to trigger a phase 3 conrrelates trial.J Acquir Immune Defic Syndr,2007,44(2):203-212. 被引量:1
  • 5Rerks-Ngarm S,Pitisuttithum P,Nitayaphan S,et al.Vaccinmion with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.N Engl J Med,2009,361(23):2209-2220. 被引量:1
  • 6Quinnan GV Jr,Zhang PF,Fu DW,et al.Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response.AIDS Res Hum Retroviruses,1999,15(6):561-570. 被引量:1
  • 7Zhang PF,Cham F,Dong M,et al.Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.Proc Natl Acad Sci USA,2007,104(24):10193-10198. 被引量:1
  • 8Zhang PF,Bouma P,Park EJ,et al.A variable region 3(V3)mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive,primary virusneutralizing antibody response.J Virol,2002,76(2):644-655. 被引量:1
  • 9Choudhry V,Zhang MY,Sidorov IA,et al.Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140)isolated from a patient(R2)with broadly HIV-1 neutralizing antibodies.Virology,2007,363(1):79-90. 被引量:1
  • 10McBurney SP,Ross TM.Viral sequence diversity:challenges for AIDS vaccine designs.Expert Rev Vaccines,2008,7(9):1405-1417. 被引量:1

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部